Chongqing Claruvis Pharmaceutical, a subsidiary of MingMed Biotechnology, has announced that China's National Medical Products Administration (NMPA) has approved its Retoxin® (recombinant botulinum toxin type A, project code YY001) for the temporary improvement of moderate-to-severe glabellar lines in adult patients. This approval marks a significant technological shift from traditional botulinum toxin products derived from Clostridium botulinum extraction to a precision-engineered recombinant manufacturing process. Retoxin® is the world's first approved recombinant botulinum toxin type A. Developed using Claruvis Pharmaceutical's proprietary recombinant platform and manufacturing system, Retoxin® preserves the active protein molecular structure (the core 150kDA neurotoxin structure) while eliminating biosafety risks associated with traditional Clostridium botulinum-derived production, delivering a toxin with high purity and high specific activity. Claruvis Pharmaceutical is also advancing Retoxin® for the treatment of adult upper limb spasticity secondary to stroke or traumatic brain injury. The company has successfully completed Phase II clinical trials in China and is currently enrolling patients in a multicenter Phase III program across more than 20 clinical sites in China. With its quality advantages, Retoxin® aims to offer a safer, more effective treatment option for patients suffering from debilitating spasticity.
Source: Read the original report | Published: April 29, 2026